Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia.
COVID-19
Hydroxychloroquine
Infectious Disease
fever clinics
outpatient setting
safety outcome
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
20
08
2020
revised:
07
10
2020
accepted:
10
10
2020
pubmed:
20
10
2020
medline:
14
1
2021
entrez:
19
10
2020
Statut:
ppublish
Résumé
Global healthcare is challenged following the COVID-19 pandemic, since late 2019. Multiple approaches have been performed to relieve the pressure and support existing healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5 A cross-sectional study included 2,733 patients subjected to MOH treatment protocol (hydroxychloroquine) and followed-up within 3-7 days after initiation. Data was collected through an electronic link and cross-checked with the national database (Health Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality (M&M) Committee. 240 patients (8.8%) discontinued treatment because of side effects (4.1%) and for non-clinical reasons in the remaining (4.7%). Adverse effects were reported among (6.7%) of all studied participants, including mainly cardiovascular (2.5%, 0.15% with QTc prolongation), and gastrointestinal (2.4%). No Intensive Care Unit admission or death were reported among these patients. Our results show that hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.
Sections du résumé
BACKGROUND
BACKGROUND
Global healthcare is challenged following the COVID-19 pandemic, since late 2019. Multiple approaches have been performed to relieve the pressure and support existing healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5
METHOD
METHODS
A cross-sectional study included 2,733 patients subjected to MOH treatment protocol (hydroxychloroquine) and followed-up within 3-7 days after initiation. Data was collected through an electronic link and cross-checked with the national database (Health Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality (M&M) Committee.
RESULTS
RESULTS
240 patients (8.8%) discontinued treatment because of side effects (4.1%) and for non-clinical reasons in the remaining (4.7%). Adverse effects were reported among (6.7%) of all studied participants, including mainly cardiovascular (2.5%, 0.15% with QTc prolongation), and gastrointestinal (2.4%). No Intensive Care Unit admission or death were reported among these patients.
CONCLUSION
CONCLUSIONS
Our results show that hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.
Identifiants
pubmed: 33075525
pii: S1201-9712(20)32235-9
doi: 10.1016/j.ijid.2020.10.031
pmc: PMC7567693
pii:
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110-114Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Ann Intern Med. 2020 Oct 20;173(8):623-631
pubmed: 32673060
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Open Forum Infect Dis. 2020 Oct 19;7(11):ofaa500
pubmed: 33204764
Int J Infect Dis. 2020 May;94:44-48
pubmed: 32171952
Heart Rhythm. 2020 Nov;17(11):1930-1935
pubmed: 32610165
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
PLoS One. 2020 Jul 23;15(7):e0236778
pubmed: 32701969
Travel Med Infect Dis. 2020 Jul - Aug;36:101812
pubmed: 32645478
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282